On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- National Rail Tentative Agreement Update: Q&As Complete, Voting Set to Begin
- Statement from SMART General President Michael Coleman
- From Skeptic to Supporter: Members Work Across the Aisle to Tackle Rail Safety
- Two Training Tracks Are FULL for Upcoming Atlanta Regional Meeting
- How Does a Government Shutdown Impact the Offices Members Rely On?
- The Truth From Within: General Chairpersons From CSX Statement on Departure of CEO Joe Hinrichs
- Update on National Rail Contract –Make Sure You Get Your Ballot
- Statement from GP Coleman: Canada’s National Day for Truth and Reconciliation
- New law would end unfair taxation on workers’ strike pay
- Two RRB Field Offices Move to New Locations